Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2158478 | 0.88 | MCHR1 (0.39) | MCHR1 | |
| SCHEMBL2157717 | 0.85 | MEN1 (0.43) | CHRM2CHRM3MEN1KMT2A | |
| SCHEMBL2158079 | 0.83 | PPARA (0.35) | MCHR1 | |
| SCHEMBL2158448 | 0.82 | NPY1R (0.38) | CHRM2CHRM3MEN1KMT2AMCHR1 | |
| SCHEMBL2157419 | 0.79 | NPY1R (0.36) | CHRM2CHRM3MEN1KMT2AMCHR1 | |
| SCHEMBL2157549 | 0.78 | P2RX7 (0.40) | MGLL | |
| SCHEMBL6426599 | 0.77 | USP30 (0.47) | MEN1KMT2AMCHR1 | |
| SCHEMBL2157793 | 0.77 | NPY1R (0.38) | MEN1KMT2AMCHR1 | |
| SCHEMBL6429208 | 0.76 | PDK2 (0.38) | MCHR1 | |
| SCHEMBL6426877 | 0.76 | KMT2A (0.60) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | HAVCR2, ZC3HAV1, MAVS | CHRM2 4876/4885CHRM3 4703/4885MEN1 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.